Workflow
HUAPONT LIFE SCIENCES(002004)
icon
Search documents
华邦健康:上半年净利润同比增长23.9% 拟10派2元
人民财讯8月19日电,华邦健康(002004)8月19日晚间披露2025年半年报,公司上半年实现营业收入 59.45亿元,同比增长0.39%;归母净利润3.88亿元,同比增长23.9%;基本每股收益0.1969元。公司拟每 10股派发现金红利2元(含税)。报告期内,农化板块需求回暖,带动公司农化相关产品的订单增加。同 时,原材料液氯采购价格维持相对低位,多因素协同发力,公司主要产品的出货量及毛利均有所上升, 推动公司业绩较去年同期增长明显。 ...
华邦健康: 2025年半年度财务报告
Zheng Quan Zhi Xing· 2025-08-19 09:17
Core Viewpoint - The financial report of Huabang Life Health Co., Ltd. for the first half of 2025 shows a slight increase in total revenue and a significant rise in net profit compared to the same period in 2024, indicating a positive financial performance despite some fluctuations in costs and expenses [1]. Financial Statements Assets - Total assets at the end of the period amounted to 29,654,478,331.32 yuan, an increase from 29,450,469,334.61 yuan at the beginning of the period [2][3]. - Current assets totaled 11,538,794,816.33 yuan, up from 11,276,705,434.24 yuan [2]. - Non-current assets were reported at 18,115,683,514.99 yuan, slightly down from 18,173,763,900.37 yuan [2]. Liabilities - Total liabilities decreased to 13,690,632,642.71 yuan from 13,977,060,015.24 yuan [3]. - Current liabilities were 9,379,962,735.70 yuan, down from 10,415,060,826.26 yuan [3]. - Non-current liabilities increased to 4,310,669,907.01 yuan from 3,561,999,188.98 yuan [3]. Equity - Total equity rose to 15,963,845,688.61 yuan from 15,473,409,319.37 yuan [3]. - The company's retained earnings increased to 1,986,457,656.65 yuan from 1,598,002,031.15 yuan [3]. Income Statement - Total operating revenue for the first half of 2025 was 5,945,032,088.09 yuan, slightly up from 5,922,042,354.85 yuan in the same period of 2024 [4]. - Total operating costs decreased to 5,353,287,909.61 yuan from 5,370,629,390.07 yuan [4]. - Net profit for the period was 549,873,387.16 yuan, compared to 424,208,862.87 yuan in the previous year, reflecting a significant increase [5]. Cash Flow Statement - Net cash flow from operating activities was 536,502,508.00 yuan, an increase from 367,219,592.32 yuan [6]. - Net cash flow from investing activities was 263,981,575.71 yuan, a turnaround from a negative cash flow of -534,976,367.90 yuan [6]. - Net cash flow from financing activities was -517,407,309.94 yuan, compared to a positive cash flow of 306,299,407.34 yuan in the previous year [6].
华邦健康: 半年度非经营性资金占用及其他关联资金往来情况汇总表
Zheng Quan Zhi Xing· 2025-08-19 09:17
| 陕西汉江药业集团股份有限公司 | | | | 子公司 | 应收股利 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 7,088.26 | - | - | | 7,088.26 | - | 分配股利 | 非经营性往来 | | | | 重庆华邦制药有限公司 | | | | 子公司 | 应收股利 | | 40,036.98 | 8,025.93 | - | | 48,062.91 | - | 分配股利 | 非经营性往来 | | | | | | | | 其他关联方及其附属 | 重庆松山医院 | | | | 其他关联方 | 应收账款 | 25,624.91 | | | | 12,194.67 | | 2,904.75 | | | 34,914.83 销售及租赁等业务 | 经营性往来 | | | | | 企业 | 重庆松山医院 | | | 其他关联方 | 其他应收款 | | 45,150.61 | 14,126.00 | | | 751.67 | 18,226.00 | 41,802.28 | | 借款 非经营性往来 ...
华邦健康: 关于召开2025年半年度业绩网上说明会的公告
Zheng Quan Zhi Xing· 2025-08-19 09:17
华邦生命健康股份有限公司(以下简称"公司")已于 2025 年 8 月 20 日在 巨潮资讯网(www.cninfo.com.cn)披露了公司《2025 年半年度报告》及其摘要。 为使广大投资者进一步了解公司经营情况,公司拟于 2025 年 8 月 26 日(星期二) 下午 15:00-17:00 在全景网举行 2025 年半年度业绩说明会,本次说明会将采用网 络远程方式举行,投资者可登陆"全景•路演天下"(http://rs.p5w.net)参与本次 业绩说明会。出席本次业绩说明会的人员有:公司董事、总经理张海安先生,独 立董事刘忠海先生,董事会秘书胡菁菁女士,财务总监王剑先生。 为充分尊重投资者、提升交流的针对性,现就公司 2025 年半年度业绩说明 会提前向投资者征集相关问题,广泛听取投资者建议。投资者可在 2025 年 8 月 征集专题页面。公司将在说明会上对投资者普遍关注的问题进行回答。 公司董事会及管理层衷心感谢广大投资者对公司的关注与支持,欢迎广大投 资者积极参与。 (问题征集专题页面二维码) 华邦生命健康股份有限公司 证券代码:002004 证券简称:华邦健康 公告编号:2025040 华邦生 ...
华邦健康: 半年报董事会决议公告
Zheng Quan Zhi Xing· 2025-08-19 09:14
Meeting and Resolutions - The second meeting of the ninth board of directors of Huabang Life Health Co., Ltd. was held on August 18, 2025, via remote voting, with all six directors participating [1] - The meeting approved the "2025 Semi-Annual Report" and its summary with a unanimous vote of 6 in favor, 0 against, and 0 abstentions [1] - The meeting also approved the "2025 Mid-Year Profit Distribution Plan" with the same voting results [2] Profit Distribution Plan - The proposed profit distribution plan for the first half of 2025 is to distribute profits without issuing bonus shares or converting capital reserves into share capital [2] - This proposal will be submitted for review at the company's first extraordinary general meeting of shareholders in 2025 [2] Extraordinary General Meeting - The board approved the proposal to convene the first extraordinary general meeting of shareholders in 2025, also with a unanimous vote [2]
华邦健康: 2025年中期利润分配预案
Zheng Quan Zhi Xing· 2025-08-19 09:14
Core Viewpoint - The company has proposed a profit distribution plan for the first half of 2025, aiming to enhance investment value and share development results with investors [1][2]. Group 1: Profit Distribution Proposal - The board of directors has approved the profit distribution plan, which will be submitted to the first extraordinary general meeting of shareholders in 2025 for review [1]. - The net profit attributable to shareholders of the listed company is approximately 388.46 million yuan, with available profits for distribution amounting to approximately 1.99 billion yuan in consolidated statements and approximately 775.94 million yuan in the parent company [1][2]. Group 2: Cash Dividend Plan - The company plans to distribute cash dividends of approximately 394.57 million yuan (including tax), with the actual amount subject to the distribution situation [2]. - The cash dividend plan complies with relevant laws and regulations, ensuring that it does not affect the company's liquidity or debt repayment ability [2]. Group 3: Compliance and Future Plans - The profit distribution plan aligns with the company's valuation enhancement plan and considers the reasonable interests of investors while ensuring normal operations and long-term development [2]. - The company has not used raised funds to supplement working capital in the past twelve months and does not plan to do so in the next twelve months [2].
华邦健康: 2025年半年度报告
Zheng Quan Zhi Xing· 2025-08-19 09:14
Core Viewpoint - Huapont Life Sciences Co., Ltd. reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating strong performance across its business segments, particularly in pharmaceuticals and healthcare services [9][12][15]. Company Overview and Financial Indicators - The company operates in five major sectors: pharmaceuticals, healthcare, agrochemicals, new materials, and tourism, with a focus on skin health and clinical medications [11][12]. - Total revenue for the reporting period was approximately CNY 5.95 billion, a 0.39% increase year-on-year [9]. - Net profit attributable to shareholders was approximately CNY 388.46 million, reflecting a 23.90% increase compared to the previous year [9]. - The company’s total assets reached approximately CNY 29.65 billion, up 0.69% from the end of the previous year [9]. Business Segments Pharmaceuticals - The company emphasized product development, achieving A certification for raw materials and obtaining market approval for six new formulations, including a first-of-its-kind psoriasis treatment [12][15]. - The pharmaceutical segment is expanding its market presence both domestically and internationally, with a focus on prescription markets and new product launches [12][15]. Healthcare - The company is enhancing its healthcare services through the establishment of specialized clinics and hospitals, focusing on quality care and expanding service offerings [13][18]. - The Chongqing Songshan Hospital has added new specialty clinics and increased its bed capacity, indicating growth in healthcare service demand [13][18]. Agrochemicals - The agrochemical sector is experiencing a recovery, with improved profitability driven by seasonal demand and rising prices for certain products [14][24]. - The company has a comprehensive product line in agrochemicals, including herbicides and insecticides, and is actively expanding its market reach [24]. New Materials - The new materials segment focuses on high-performance polymers and fine chemicals, with a strong emphasis on research and development [24]. - The company is recognized as a leading producer of chlorosulfonic acid and aramid polymer intermediates, catering to various industries [24]. Tourism - The tourism business is leveraging popular scenic spots to enhance visitor experiences, with operations in transportation and hospitality [25]. - The company is actively managing several hotels and transportation services in key tourist destinations, contributing to its overall revenue growth [25].
华邦健康: 2025年半年度报告摘要
Zheng Quan Zhi Xing· 2025-08-19 09:14
Core Viewpoint - The report highlights the financial performance of Huabong Life Health Co., Ltd. for the first half of 2025, showing an increase in revenue and net profit compared to the same period last year. Financial Performance - Operating revenue for the reporting period reached CNY 5,945,032,088.09, a slight increase of 0.39% from CNY 5,922,042,354.85 in the previous year [1]. - Net profit attributable to shareholders was CNY 388,455,625.50, representing a significant increase of 23.90% from CNY 313,522,665.65 [1]. - The net profit after deducting non-recurring gains and losses was also reported, but specific figures were not provided [1]. - The net cash flow from operating activities increased by 46.10% to CNY 536,502,508.00 from CNY 367,219,592.32 [1]. - Basic and diluted earnings per share rose to CNY 0.1969, up 24.15% from CNY 0.1586 [1]. Asset and Equity Position - Total assets at the end of the reporting period were CNY 29,654,478,331.32, a 0.69% increase from CNY 29,450,469,334.61 at the end of the previous year [2]. - Net assets attributable to shareholders increased by 4.41% to CNY 9,748,372,423.62 from CNY 9,337,058,173.60 [2]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 73,829 [2]. - The largest shareholder, Chongqing Huabong Zhuoyuan Technology Co., Ltd., holds 18.71% of the shares [2]. - The report indicates that there were no changes in the controlling shareholder or actual controller during the reporting period [6]. Debt and Financial Ratios - The debt-to-asset ratio at the end of the reporting period was 46.17%, down from 47.46% [4]. - The EBITDA interest coverage ratio improved to 9.17 from 7.07 in the previous year [4].
华邦健康:8月18日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-08-19 09:01
Group 1 - The core point of the article is that Huabang Health announced the convening of its 2025 first extraordinary shareholders' meeting through a communication vote on August 18, 2025 [2] - The revenue composition for Huabang Health in 2024 is as follows: pesticides account for 56.52%, pharmaceuticals for 26.22%, tourism for 9.46%, others for 4.66%, and healthcare for 3.15% [2]
华邦健康:2025年半年度净利润约3.88亿元,同比增加23.9%
Mei Ri Jing Ji Xin Wen· 2025-08-19 08:54
(文章来源:每日经济新闻) 华邦健康(SZ 002004,收盘价:4.55元)8月19日晚间发布半年度业绩报告称,2025年上半年营业收入 约59.45亿元,同比增加0.39%;归属于上市公司股东的净利润约3.88亿元,同比增加23.9%;基本每股 收益0.1969元,同比增加24.15%。 ...